Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0J4MY
|
|||
Former ID |
DCL000333
|
|||
Drug Name |
Tasidotin hydrochloride
|
|||
Synonyms |
Tasidotin HCl; BSF 223651; ILX 651; LU 223651; Tasidotin hydrochloride (USAN)
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [1] | |
Company |
Genzyme
|
|||
Structure |
Download2D MOL |
|||
Formula |
C32H59ClN6O5
|
|||
Canonical SMILES |
CC(C)C(C(=O)N(C)C(C(C)C)C(=O)N1CCCC1C(=O)N2CCCC2C(=O)NC(C)(C)C)NC(=O)C(C(C)C)N(C)C.Cl
|
|||
InChI |
1S/C32H58N6O5.ClH/c1-19(2)24(33-28(40)25(20(3)4)35(10)11)30(42)36(12)26(21(5)6)31(43)38-18-14-16-23(38)29(41)37-17-13-15-22(37)27(39)34-32(7,8)9;/h19-26H,13-18H2,1-12H3,(H,33,40)(H,34,39);1H/t22-,23-,24-,25-,26-;/m0./s1
|
|||
InChIKey |
OOKIODJYZSVHDO-QMYFOHRPSA-N
|
|||
CAS Number |
CAS 623174-20-9
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Tubulin beta (TUBB) | Target Info | Binder | [2] |
KEGG Pathway | Phagosome | |||
Gap junction | ||||
Pathogenic Escherichia coli infection | ||||
NetPath Pathway | FSH Signaling Pathway | |||
TCR Signaling Pathway | ||||
EGFR1 Signaling Pathway | ||||
Panther Pathway | Cytoskeletal regulation by Rho GTPase | |||
Huntington disease | ||||
Reactome | Regulation of PLK1 Activity at G2/M Transition | |||
Loss of Nlp from mitotic centrosomes | ||||
Recruitment of mitotic centrosome proteins and complexes | ||||
Loss of proteins required for interphase microtubule organization?from the centrosome | ||||
Anchoring of the basal body to the plasma membrane | ||||
WikiPathways | Parkin-Ubiquitin Proteasomal System pathway | |||
Pathogenic Escherichia coli infection | ||||
Mitotic G2-G2/M phases |
References | Top | |||
---|---|---|---|---|
REF 1 | Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors.Clin Cancer Res. 2006 Sep 1;12(17):5207-15. | |||
REF 2 | Intracellular activation and deactivation of tasidotin, an analog of dolastatin 15: correlation with cytotoxicity. Mol Pharmacol. 2009 Jan;75(1):218-26. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.